Related Experiment Video

Updated: Nov 13, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.6K

Bispecific anti-OX40/5T4 antibodies for cancer treatment

Martin Perez-Santos1

  • 1Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Puebla, CP, 72570, México.

Pharmaceutical Patent Analyst
|March 12, 2021
PubMed

Insights

A novel bispecific antibody targeting OX40 and 5T4 molecules shows potential for cancer treatment by activating T-cells. This approach could lead to new therapies for neoplastic disorders.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • OX40 is a molecule crucial for T-cell expansion.
  • 5T4 is implicated in cancer-associated cytoskeleton disruption.
  • Bispecific antibodies offer targeted therapeutic strategies.

Purpose of the Study:

  • To analyze the US201916155 patent concerning a bispecific antibody targeting OX40 and 5T4.
  • To evaluate the potential of this bispecific antibody in cancer treatment.

Main Methods:

  • Patent claim analysis.
  • Chemical and biological information analysis of the bispecific antibody.
  • Review of patent claims covering antibody, DNA, vector, host cell, pharmaceutical composition, and medical use.

Main Results:

  • The patent describes bispecific antibodies targeting both OX40 and 5T4.
  • These antibodies are claimed for use in treating or preventing neoplastic disorders.
  • The bispecific antibodies can activate Interleukin-2 (IL-2) secretion in CD4+ T cells.

Conclusions:

  • The bispecific antibody targeting OX40/5T4 represents a promising therapeutic candidate for cancer.
  • This antibody has the potential to enhance anti-tumor immune responses through T-cell activation.
  • The patent outlines a comprehensive approach for the development and application of this novel cancer therapy.
Keywords:
5T4OX40bispecificcancerimmunotherapypatent

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.4K
Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
826
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K